Cover Image
市場調查報告書

肝硬化:全球臨床實驗檢討 (2015年前半期)

Cirrhosis Global Clinical Trials Review, H2, 2016

出版商 GlobalData 商品編碼 324947
出版日期 內容資訊 英文 493 Pages
訂單完成後即時交付
價格
Back to Top
肝硬化:全球臨床實驗檢討 (2015年前半期) Cirrhosis Global Clinical Trials Review, H2, 2016
出版日期: 2016年10月31日 內容資訊: 英文 493 Pages
簡介

本報告提供肝硬化相關之臨床研究最新趨勢調查,提供您地區·進展·PHASE·募集情況別之實驗量,代表性贊助商,開發中的治療藥資訊,並彙整全球各國的主要企業·機關的進展狀況,及有潛力的藥劑比較等資訊。

目錄

  • 簡介
    • 肝硬化
    • 報告指南
  • 各地區的臨床實驗數量
    • 各國臨床實驗數量和平均實驗人數
      • 亞太地區主要5個國家的臨床實驗數量
      • 歐洲主要5個國家的臨床實驗數量
      • 北美主要國家的臨床實驗數量
      • 中東·非洲主要5個國家的臨床實驗數量
      • 中南美主要5個國家的臨床實驗數量
  • G7各國臨床實驗數量:消化器官系統臨床實驗中肝硬化的比例
  • G7各國臨床實驗數量:Phase別
  • G7各國臨床實驗數量:各進展狀況
  • E7各國臨床實驗數量:消化器官系統臨床實驗中肝硬化的比例
  • E7各國臨床實驗數量:Phase別
  • E7各國臨床實驗數量:各進展狀況
  • Phase別臨床實驗數量
    • 進行中的臨床實驗:Phase別
  • 各進展狀況臨床實驗數量
  • 臨床實驗的目標達成情形
  • 未完成的臨床實驗數量:肝硬化的情況
  • 一定期間所採用的實驗對像
  • 贊助商類別的臨床實驗數量
  • 有潛力的贊助商
    • 肝硬化治療藥臨床實驗的主要參與企業
  • 有潛力的藥劑
  • 最新臨床實驗新聞:肝硬化相關
  • 臨床實驗簡介
    • 主要企業臨床實驗概要
      • Merck & Co., Inc
      • Novartis AG
      • Genextra S.p.a.
      • GlaxoSmithKline plc
      • F. Hoffmann - La Roche Ltd.
      • Zambon Company S.p.A.
      • Sanofi
      • 大塚集團
      • AbbVie Inc.
      • Pfizer Inc.
    • 有代表性的研究機關·醫院臨床實驗概要
      • Hospital Clinic de Barcelona
      • The National Institute of Diabetes and Digestive and Kidney Diseases
      • Assistance Publique-Hopitaux de Paris
      • Instituto Nacional de Ciencias Medicas y Nutricion薩爾瓦多Zubiran
      • Govind Ballabh Pant Hospital
      • Institute of Liver and Biliary Sciences
      • Sun Yat-sen University
      • Beijing Friendship Hospital
      • Mayo Clinic
      • Fundacio Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
  • 5個有代表性的臨床實驗簡介
  • 附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHC3836CTIDB

GlobalData's clinical trial report, "Cirrhosis Global Clinical Trials Review, H2, 2016" provides an overview of Cirrhosis clinical trials scenario. This report provides top line data relating to the clinical trials on Cirrhosis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Reasons to buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Report Guidance
  • Clinical Trials by Region
    • Clinical Trials and Average Enrollment by Country
      • Top Five Countries Contributing to Clinical Trials in Asia-Pacific
      • Top Five Countries Contributing to Clinical Trials in Europe
      • Top Countries Contributing to Clinical Trials in North America
      • Top Five Countries Contributing to Clinical Trials in Middle East and Africa
      • Top Five Countries Contributing to Clinical Trials in Central and South America
  • Clinical Trials by G7 Countries: Proportion of Cirrhosis to Gastrointestinal Clinical Trials
  • Clinical Trials by Phase in G7 Countries
  • Clinical Trials in G7 Countries by Trial Status
  • Clinical Trials by E7 Countries: Proportion of Cirrhosis to Gastrointestinal Clinical Trials
  • Clinical Trials by Phase in E7 Countries
  • Clinical Trials in E7 Countries by Trial Status
  • Clinical Trials by Phase
    • In Progress Trials by Phase
  • Clinical Trials by Trial Status
  • Clinical Trials by End Point Status
  • Subjects Recruited Over a Period of Time
  • Clinical Trials by Sponsor Type
  • Prominent Sponsors
    • Top Companies Participating in Cirrhosis Therapeutics Clinical Trials
  • Prominent Drugs
    • Latest Clinical Trials News on Cirrhosis
      • Oct 03, 2016: Conatus Pharmaceuticals Announces Acceptance of Emricasan Abstracts for AASLD Annual Meeting
      • Sep 19, 2016: Ocera Initiates Phase 1 Clinical Study of Orally Available OCR-002 in Patients with Cirrhosis for the Prevention of Hepatic Encephalopathy
      • Aug 02, 2016: Galectin Therapeutics Announces Completion of Patient Recruitment in its Phase 2 Trial with GR-MD-02 in NASH Patients with Cirrhosis
  • Clinical Trial Profile Snapshots
  • Appendix
    • Abbreviations
    • Definitions
    • Research Methodology
    • Secondary Research
    • About GlobalData
    • Contact Us
    • Disclaimer
    • Source

List of Tables

  • Cirrhosis Therapeutics, Global, Clinical Trials by Region, 2016*
  • Cirrhosis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016*
  • Cirrhosis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016*
  • Cirrhosis Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2016*
  • Cirrhosis Therapeutics Clinical Trials, Europe, Top Five Countries, 2016*
  • Cirrhosis Therapeutics Clinical Trials, North America, Top Countries, 2016*
  • Cirrhosis Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2016*
  • Cirrhosis Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2016*
  • Proportion of Cirrhosis to Gastrointestinal Clinical Trials, G7 Countries (%), 2016*
  • Cirrhosis Therapeutics, G7 Countries, Clinical Trials by Phase, 2016*
  • Cirrhosis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016*
  • Proportion of Cirrhosis to Gastrointestinal Clinical Trials, E7 Countries (%), 2016*
  • Cirrhosis Therapeutics, E7 Countries, Clinical Trials by Phase, 2016*
  • Cirrhosis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016*
  • Cirrhosis Therapeutics, Global, Clinical Trials by Phase, 2016*
  • Cirrhosis Therapeutics, Global, Clinical Trials In Progress by Phase 2016*
  • Cirrhosis Therapeutics, Global, Clinical Trials by Trial Status, 2016*
  • Cirrhosis Therapeutics Clinical Trials, Global, by End Point Status, 2016*
  • Cirrhosis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015
  • Cirrhosis Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016*
  • Cirrhosis Therapeutics Clinical Trials, Global, Key Sponsors, 2016*
  • Cirrhosis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016*
  • Cirrhosis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016*

List of Figures

  • Cirrhosis Therapeutics, Global, Clinical Trials by Region (%), 2016*
  • Cirrhosis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016*
  • Cirrhosis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016*
  • Cirrhosis Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2016*
  • Cirrhosis Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016*
  • Cirrhosis Therapeutics Clinical Trials, North America, Top Countries (%), 2016*
  • Cirrhosis Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2016*
  • Cirrhosis Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2016*
  • Proportion of Cirrhosis to Gastrointestinal Clinical Trials, G7 Countries (%), 2016*
  • Cirrhosis Therapeutics, G7 Countries, Clinical Trials by Phase, 2016*
  • Cirrhosis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016*
  • Proportion of Cirrhosis to Gastrointestinal Clinical Trials, E7 Countries (%), 2016*
  • Cirrhosis Therapeutics, E7 Countries, Clinical Trials by Phase, 2016*
  • Cirrhosis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016*
  • Cirrhosis Therapeutics, Global, Clinical Trials by Phase (%), 2016*
  • Cirrhosis Therapeutics, Global, Clinical Trials In Progress by Phase, 2016*
  • Cirrhosis Therapeutics, Global, Clinical Trials by Trial Status, 2016*
  • Cirrhosis Therapeutics Clinical Trials, Global, by End Point Status, 2016*
  • Cirrhosis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015
  • Cirrhosis Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016*
  • Cirrhosis Therapeutics Clinical Trials, Global, Key Sponsors, 2016*
  • Cirrhosis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016*
  • Cirrhosis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016*
  • GlobalData Methodology
Back to Top